Senores Pharmaceuticals is engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets.

Identifies and develops a diverse range of specialty, underpenetrated, and complex pharmaceutical products, and manufactures critical care injectables and APIs. As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments.

The product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine...

• 

  (28-Jan-25 13:15)

  Dr. Agarwals Health Care
• 

  (21-Jan-25 17:59)

  Denta Water and Infra Solutions
• 

  (15-Jan-25 21:10)

  Stallion India Flurochemicals
• 

  (10-Jan-25 14:47)

  Laxmi Dental

• Hot Pursuit   (23-Jan-25 15:02)

  Senores Pharma spurts as PAT jumps to Rs 16 cr in Q3 FY25

• Results - Announcements   (23-Jan-25 14:48)

  Senores Pharmaceuticals consolidated net profit rises 141.97% in the December 2024 quarter

• Corporate News   (11-Jan-25 10:25)

  Senores Pharmaceuticals to conduct board meeting

• Hot Pursuit   (10-Jan-25 10:49)

  Senores Pharma gets final approval for Metoprolol Tartrate and Hydrochlorothiazide tablets

• Corporate News   (10-Jan-25 10:23)

  Senores Pharmaceuticals receives USFDA approval for Metoprolol Tartrate and Hydrochlorothiazide Tablet

• Hot Pursuit   (30-Dec-24 10:27)

  Senores Pharmaceuticals makes strong debut

• IPO Centre - IPO News   (26-Dec-24 12:24)

  Senores Pharmaceuticals IPO ends with 93.69x subscription